Cytomx Therapeutics, INC. (CTMX) SEC Filings — 2025

Filings

• CytomX Q3 Revenue Plunges 82% Amidst Net Loss, Bolstered by Equity Raise — 10-Q · Nov 6, 2025
• CytomX Therapeutics Files 8-K — 8-K · Aug 13, 2025
• CytomX Losses Widen Amid R&D Spend, Revenue Dip — 10-Q · Aug 7, 2025
• CytomX Therapeutics Files 8-K on Officer/Director Changes — 8-K · Jun 13, 2025
• CytomX Therapeutics Files 8-K — 8-K · May 28, 2025
• CytomX Therapeutics Files 8-K — 8-K · May 13, 2025
• CytomX Therapeutics Files 8-K on Financials and Operations — 8-K · May 12, 2025
• CytomX Therapeutics Files Q1 2025 10-Q — 10-Q · May 12, 2025
• CytomX Therapeutics Files Definitive Proxy Statement — DEF 14A · Apr 28, 2025
• CytomX Therapeutics Files 2024 10-K — 10-K · Mar 6, 2025
• CytomX Therapeutics Faces Listing Rule Issues — 8-K · Feb 26, 2025
• CytomX Therapeutics Appoints New CMO, CSO, and Directors — 8-K · Feb 3, 2025
• CytomX Therapeutics Reports Exit/Disposal Costs — 8-K · Jan 6, 2025